Intravenous (IV) Iron Drugs - 2015 Global Strategic Business Report - A Glimpse of Regulations in the US and Europe

DUBLIN, Mar. 13, 2015 /PRNewswire/ --Research and Markets

(http://www.researchandmarkets.com/research/qn3kz9/intravenous_iv) has announced the addition of the "Intravenous (IV) Iron Drugs - Global Strategic Business Report" report to their offering.

This report analyzes the worldwide markets for Intravenous (IV) Iron Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.

Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

The report profiles 17 companies including many key and niche players such as:

• Actavis, Inc. (US)
• AMAG Pharmaceuticals, Inc. (US)
• Fresenius Medical Care AG & Co. KGaA (Germany)
• Galenica Ltd. (Switzerland)
• Vifor Pharma Ltd. (Switzerland)
• Luitpold Pharmaceuticals, Inc. (US)
• American Regent, Inc. (US)
• Pharmacosmos A/S (Denmark)
• Sanofi US (US)
• Takeda Pharmaceutical Company Limited (Japan)

Key Topics Covered:

1. OUTLOOK

• IV Iron Drugs Market
• A Quick Primer
• US and Europe Dominate IV Iron Market
• Asia-Pacific
• The Fastest Growing Market
• Recession Fails to Affect Market Growth
• Positive Outlook for the Healthcare Industry Signals Prospects

2. INDUSTRY OVERVIEW & TRENDS

• IDA and Treatment
• An Overview
• Dialysis Clinics
• Major Market for IV Iron Supplements
• IV Iron Drugs
• An Overview
• Select IV Iron Drugs Prescribed for Iron Deficiency
• Galenica
• The Global Leader in IV Iron
• Venofer®
• Galenica's Wonder Drug
• Venofer Continues to Lose Ground
• Ferinject/Injectafer
• A Promising Revenue Spinner for Galenica
• Feraheme Surges Ahead; Manufacturer Eyes Expansion of Indications
• The Vulnerable Ageing Population Supports Demand
• Changing Preferences Favor IV Iron Drugs
• Comparison of Ferrous Salts with IV Iron Therapy
• Chronic Kidney Disease
• The Predominant Growth Factor
• Other Chronic Diseases with IDA Offer Prospects for IV Iron Drugs
• Anemia in Heart Failure
• A Market with Huge Potential
• Chemotherapy Induced Anemia to Promote IV Iron Supplements
• Correction of IDA in Pregnancy Signals Opportunities
• Women's Health
• Key Growth Opportunity
• Perioperative and Postoperative Anemia
• A Niche Market Beckons
• Adverse Reactions of IV Iron Preparations Raise Concerns
• Peginesatide
• A Possible Threat to IV Iron
• Dosing Limitations Plague IV Iron Market
• Select Therapeutic Areas and the Required Iron Doses

3. REGULATORY OVERVIEW

• Increasing Trend towards Bundled Reimbursements
• A Glimpse of Regulations in the US and Europe
• Comparison of Approved Indications and Safety Warnings for Select FDA Approved IV Iron Drugs
• Coverage of IV Iron and ESA in the Reimbursement Packages of Dialysis Services across Belgium, Germany, Netherlands, the UK, France, the US and Ontario, Canada

4. OVERVIEW OF INTRAVENOUS (IV) IRON DRUGS

• Iron
• A Vital Element
• Iron-Deficiency Anemia
• Intravenous Therapy
• Patients of Chronic Illnesses, the Elderly and Women
• The High Risk Population
• Treatment for Iron Deficiency Anemia
• Iron Requirement in Chronic Kidney Disease
• Classification of Iron Deficiency in CKD
• Treating Iron Deficiency in CKD Patients
• Side Effects of Iron Supplementation in CKD
• Methods of Restoring Iron
• Oral Iron Therapy
• IV Iron-Infusion Therapy
• Intravenous (IV) Iron
• Conditions for Receiving Iron Injections
• Injection Procedure
• Categories of Iron Injections
• Suitability of IV Iron Preparation
• Suitability of Regimen
• Management of Iron Doses
• Effectiveness of Iron Injection
• Requirement of Test Dose
• Adverse Effects of Iron Injections
• Iron Therapy: Caution
• Duration of Iron Infusion
• Iron Overdose
• Iron-Out-of-Balance Therapies
• Blood Donation
• Therapeutic Phlebotomy
• Red Cell Apheresis
• Iron Chelation Therapy
• Iron-Chelating Drugs
• Desferrioxamine or Desferal
• Deferiprone or Ferriprox
• Conditions for Undergoing Iron Chelation Therapy
• Kinds of Chelation Therapy
• Side Effects Caused by IV Iron Chelation

5. PRODUCT LAUNCHES/APPROVALS

• FDA approves Injectafer® for the Treatment of IDA
• Takeda Pharmaceutical Company Introduces Rienso® in Europe
• Pharmacosmos Launches Monofer® Intravenous Iron Drug

6. RECENT INDUSTRY ACTIVITY

• American Regent Steps Up Injectafer® Promotions
• AMAG Files for Rienso Label Expansion in Europe
• AMAG Receives FDA Complete Response Letter for Feraheme®
• Vifor Pharma and Zeria Pharmaceutical Co., Ltd. Sign Exclusive Licensing Agreement for Ferinject® in Japan
• Watson Pharmaceuticals Changes Name to Actavis
• Luitpold Pharmaceuticals Obtains FDA Acceptance for Review of Injectafer® NDA
• AMAG Pharmaceuticals Receives FDA Acceptance for Feraheme® sNDA Review
• Takeda Issues Rienso Recall in Switzerland
• EC Approves Takeda's Rienso® to Treat Anemia
• BioLink Life Sciences to Commence Phase I Trial of FCP

7. FOCUS ON SELECT PLAYERS

• Actavis, Inc. (US)
• AMAG Pharmaceuticals, Inc. (US)
• Fresenius Medical Care AG & Co. KGaA (Germany)
• Galenica Ltd. (Switzerland)
• Vifor Pharma Ltd. (Switzerland)
• Luitpold Pharmaceuticals, Inc. (US)
• American Regent, Inc. (US)
• Pharmacosmos A/S (Denmark)
• Sanofi US (US)
• Takeda Pharmaceutical Company Limited (Japan)

8. GLOBAL MARKET PERSPECTIVE

Total Companies Profiled: 17 (including Divisions/Subsidiaries 20)

• The United States (6)
• Japan (2)
• Europe (5)
• Germany (1)
• Rest of Europe (4)
• Asia-Pacific (Excluding Japan) (7)

For more information visit http://www.researchandmarkets.com/research/qn3kz9/intravenous_iv

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

Related Links

http://www.researchandmarkets.com